BTAI-logo-png-220x123.png
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
June 01, 2023 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
May 25, 2023 07:00 ET | BioXcel Therapeutics
Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program
May 16, 2023 07:00 ET | BioXcel Therapeutics
BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically  Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
May 08, 2023 07:00 ET | BioXcel Therapeutics
IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
May 02, 2023 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
April 24, 2023 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BTAI-logo-png-220x123.png
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
March 14, 2023 16:15 ET | BioXcel Therapeutics
NEW HAVEN, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 09, 2023 07:00 ET | BioXcel Therapeutics
IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
February 23, 2023 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today
February 21, 2023 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...